'Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrolment challenges that have made trial completion infeasible,' the company said in a statement late Friday.
"Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrolment challenges that have made trial completion infeasible," the company said in a statement late Friday.
This problem"made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe," it said.Hydroxychloroquine and its related compound chloroquine have traditionally been used to treat malaria and with a known anti-viral potential was seen as a possible treatment in the early days of the pandemic.
Despite recognised serious side effects, many prominent figures, including US President Donald Trump, touted it widely as a COVID-19 treatment at a time when there is no vaccine for the disease and other potentially effective drugs are only just beginning to be identified. In April, Novartis said it would sponsor a Phase III clinical trial of around 440 patients in the US using hydroxychloroquine to treat patients hospitalised with COVID-19 in agreement with the US Food and Drug Administration .
But earlier this month, the US authorities suspended its use and this week the World Health Organization said it was suspending its trials of hydroxychloroquine because it showed no ability to reduce mortality rates.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Scientists also looking at Prozac as Covid-19 treatment, but study still in early stagesAfter the breakthrough in the dexamethasone trial, scientists are still looking at treatments to help suppress the viral replication of SARS-CoV-2. Could Prozac be one of them?
Read more »
Newsdeck: Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian studyJune 18 (Reuters) - Roche's rheumatoid arthritis drug Actemra failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial.
Read more »
Immunity against Covid-19 not looking good, suggest two new studiesTwo new studies have cast a long shadow of doubt over our ability to acquire long-term immunity against Covid-19 once we’ve already had it.
Read more »
Immunity against Covid-19 not looking good, suggest two new studiesTwo new studies have cast a long shadow of doubt over our ability to acquire long-term immunity against Covid-19 once we’ve already had it.
Read more »
How to make a movie during a pandemic - The Mail & GuardianNollywood directors are having to adapt quickly to Covid-19 restrictions that make filming tricky.
Read more »
Tourism sector urged to use winter season to gear upSA Tourism CEO Sisa Ntshona says it will be a while before things get back to normal in the tourism sector
Read more »